Preparative HPLC yields a series of fractions, each with its own purity profile. But the fraction coming out of the collector is not yet an end product. Between “pure peak” and “documented research peptide in powder form” lie two steps that many introductory texts leave underexposed: deciding which fractions may be combined, and exchanging or removing the counterion left over from peptide synthesis. This article covers both steps as the logical sequel to the purification process.
From fraction to pool: which criteria determine selection
After each run every fraction is analysed separately, usually with analytical HPLC and mass spectrometry. Only fractions meeting a predefined purity criterion — in practice often a peak purity above 98% with no significant neighbouring peaks — qualify for being combined into a single pool. Fractions just below that limit, or fractions in which a shoulder peak overlaps the main peak, are kept aside or discarded.
This selection is a balance: pooling too strictly gives a smaller yield, pooling too broadly dilutes the purity of the eventual batch. Research teams record the limits used and the reasoning for including or excluding each fraction, so that the composition of the pool remains traceable down to fraction level.
Why the counterion lingers after synthesis
Peptides built via Fmoc solid-phase synthesis are usually isolated after cleavage as the trifluoroacetate (TFA) salt: the eluent of the preparative HPLC run contains TFA as an ion-pairing reagent, and that acid stays associated with the peptide backbone. For some research applications that is unproblematic, but TFA can interfere in certain assays or affect the physicochemical properties of the sample. For that reason laboratories sometimes choose to replace the counterion with acetate or chloride, both with a more favourable interference profile in subsequent analyses.
Counterion exchange in practice
There are several routes for exchanging the counterion. A commonly used method is repeated lyophilisation from a dilute acid of the desired counterion, for example acetic acid, in which TFA is gradually replaced through repeated cycles of dissolving and evaporating. An alternative route runs via ion-exchange resin: the sample is passed over a column carrying the desired counterion, exchanging TFA while the peptide binds to the matrix or passes through it, depending on the protocol chosen. Both routes require a check afterwards — usually analytical HPLC again, or ion chromatography — to confirm that the counterion exchange has been carried through completely and that no cross-contamination with the previous counterion remains.
Desalting before lyophilisation: solid-phase techniques
Besides counterion exchange, a sample often still needs desalting: buffer salts and other non-volatile components from the mobile phase must be removed before the sample is suitable for sensitive techniques such as LC-MS. Reversed-phase solid-phase extraction, generally on C18 material, is a common approach: the peptide binds to the sorbent while salts are washed away with an aqueous phase, after which the peptide is eluted with an organic solvent. This is also why “pure by HPLC” and “suitable for mass spectrometry” are two different quality criteria — a fraction can be excellent in terms of peptide purity and still contain a salt residue that disturbs the MS analysis.
From pool to powder: the final steps
Once the pool has been assembled, the counterion established or exchanged, and salts removed, lyophilisation to a stable powder follows — the subject of earlier analyses on this blog covering freeze-drying and residual moisture content. Every step in this chain (fraction selection, counterion status, desalting method) belongs in the analytical file of the batch, alongside the usual CoA data. That way the origin of a research sample stays fully reconstructable from HPLC run to final powder.
The products and information on this website are intended solely for laboratory and research purposes. They are not intended for human or animal consumption, and not for diagnostic or therapeutic use.
